Human Papilloma Virus ( Hpv )

The human papillomavirus (HPV) is a sexually transmitted disease (STD) that is very common throughout the United States and worldwide (World Health Organization (WHO), 2016). There are over 100 different forms of the virus with 13 of these types being capable of causing cancer (WHO, 2016). HPV can lead to the development of serious health problems. Theses health problems are especially an issue for adolescent women due to the highly increasing STD rates among this age group (Kostas-Polston, Johnson-Mallard & Berman, 2012). There is a vaccine for many of the common types of HPV, however, many parents are refusing to vaccinate their daughters for various reasons. With the rising cases of STDs, less birth

HPV is by far the most common sexually transmitted infection in the United States. Per the Centers for Disease Control and Prevention (CDC), 50 percent of all sexually active men and women will get it at some point in their lives, and 20 million already have it. A vaccine is available that prevents 70% of cervical cancers that arise from sexual intercourse. The human papillomavirus is unknowingly common and is diagnosed in 10,000 women a year, causing 4,000 deaths per year (“HPV Question and Answers”). If we take the responsibility to vaccinate young girls and boys, to be safe, we can eliminate many unnecessary deaths. This vaccine is a great discovery that should be put to good use, the HPV vaccine should be mandated in young teens everywhere.

One of the Healthy People 2020 initiatives or goals that I want to discuss is sexually transmitted diseases. According to Healthy People 2020 (2015) their goal is to “promote healthy sexual behaviors, strengthen community capacity, and increase access to quality services to prevent sexually transmitted diseases (STDs) and their complications.” One of their objectives in this area is to reduce HPV (human papillomavirus) infections females. I would hope to reduce the incidence of this infection by promoting safe sex, health screenings and immunizations to adolescent and adult women. Certain subtypes of HPV can lead to cervical cancer and anogenital warts (Pomfret, Gagnon Jr, & Gilchrist, 2011).

The incidence of Human Papillomavirus (HPV) in my local community Lockport, Illinois is one out of every five people have HPV and due to the vaccinations to prevent HPV, Illinois ranks 48th among the United States for incidences of HPV (Manchir, 2013). HPV is a sexually transmitted infection that is transmitted through sexual contact. HPV is transmitted during vaginal, oral, or anal sex and on rare occasions, through birth during delivery (Illinois Department of Public Health [IDPH], 2013). Surprisingly, 50 percent of men and women that are active sexually will acquire HPV during their lifetime! HPV has affected 20 million Americans and an astounding, six million additional people will become infected every year (Illinois Department of Public Health [IDPH], 2013). Although Lockport Illinois has a lower amount of people with HPV, as a public health nurse, I realize this is an issue that needs to be addressed in my local community. Awareness is the key to prevention. Teenagers, parents, and all adults need to

The debate over the HPV vaccine largely focuses on mandatory vaccination. This has become politicized because the governments are making the vaccine mandatory for girls who are being admitted into schools. This argument for or against the HPV vaccine will be looked at through ethical and economic issues. The ethical issue will focus on morality of a vaccine for a sexually transmitted infection and the question of having parental rights for mandatory vaccination. An extension to the ethical issue is whether boys should be receiving the vaccine to not just protect them from other diseases caused by HPV, but also to decrease the sexual transmission of HPV to girls. The economic issue is the cost to administer the recommended dosage. In the U.S., some families are not insured, or the insurance coverage does not include this vaccine. As well, some underdeveloped countries cannot afford the vaccine because of high purchasing costs from pharmaceutical companies. Yet, with so many scientific articles stating that the vaccine is safe, there will always be safety concerns and skepticism amongst the public.

HPV vaccination is the most common used method for preventing cervical cancer in young girls ranging from age nine to eleven years old. The overall perception of the vaccine is positive by the public because of its wide use and support by state laws, school systems and medical associations. According to the American Pediatric Association the vaccine has an excellent safety record. (Nirvi,1) A reasonable amount of parents still feel skeptical about mandatory HPV vaccination on their kids and lack great knowledge regarding the vaccine’s effectiveness.

The Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). There are over 100 types of HPV, but only 40 types affect the genital area and can cause genital warts and cervical cancer in women (“Human Papillomavirus (HPV) Vaccine”). In 2011 in the United States, 12,109 women were diagnosed with cervical cancer. Of those, 4,092 women died (“Cervical Cancer Statistics”). HPV is not only contracted from sexual intercourse, but also from skin to skin contact, including oral sex. The STI affects males and females involved in both homosexual and heterosexual sexual activities. Over 70 percent of sexually active individuals contract and carry HPV before the age of 80. In order to combat HPV two different brands of HPV vaccination – Gardasil and Cervarix – were created. Both include a vaccination plan of three shots over the course of six months. Gardasil was created by Merck & Co., and was licensed by the FDA in June 2006. The vaccine protects against HPV types 16 and 18, which lead to cervical cancer, as well as types 6 and 11, which cause 90% of genital warts. The FDA later approved Cervarix, created by GlaxoSmithKline, in 2009, which only protects against HPV types 16 and 18 (“Human Papillomavirus (HPV) Vaccine”). Originally, Gardasil was only approved for females, but three years after the release, the vaccine was approved

Many believed or thought that by receiving the HPV vaccination, girls and boys are more likely to engage in sexually risky behavior than girls and boys who did not receive the vaccine. One must ask themselves, does this vaccine actually cause promiscuity among those who have received it? A study was conducted in Ontario to test the effect that the HPV vaccine had on sexual behavior among adolescent girls. The study was conducted on girls in 8th Grade who before (2005-2007) and after (2007-2009) the girls received the vaccine. The results of the study concluded that there was no evidence that the HPV vaccine had any effect on sexual behavior of adolescent girls (Smith, L. M., Kaufman, J. S., Strumpf, E. C., & Lévesque, L. E.). These results suggest that concerns over increased promiscuity following HPV vaccination are unwarranted and should not deter from vaccinating at a young

Cervical cancer is a type of abnormal and malignant cell growth on the cervix (birth canal), which causes the common death for American Women. Infected by Human Papillomavirus (HPV) through sexual contact is the main contributor to cervical cancer. According to American Cancer Society’s (ACS) (2017) estimation, around 12,820 people will newly have cervical cancer and about 4,210 people will die from that in 2017. Therefore, it is urgent to decrease the rate of cervical cancer at women. A three-shot Gardasil series vaccine approved by the FDA for girls started to prevent cervical cancer in 2006. There are more than forty types of HPVs and the majority

The discussion section reiterates the primary purpose of this article. However, it also overlooks key data in the discussion and results sections. The prime focus is on how successful they have speculated the outcomes of the parental attitudes towards using the HPV information and the HPV vaccine. Again claiming that those in the intervention group who received the additional information reported a statistically significant increase and their perceived benefit repeatedly laid out in survey gaining 43% more likely to accept the HPV vaccine. However, more data is revealed in the descriptive and qualitative feedback section. Consequently, while the purpose is stated, generally did not determine value of the tested

Human Papilloma Virus (HPV) is currently thought to be the most common sexually transmitted infection (STI) in the United States with roughly 79 million Americans currently affected (CDC,2015). There are over 120 identified types of HPV (CDC, pink book); most of which infect the cutaneous epithelium and cause common skin warts. Approximately 40 types of HPV infect the mucosal epithelium and are categorized according to their epidemiological association with cervical cancer: low risk type is associated with non-oncogenic types and cause benign or low-grad cervical cell abnormalities, genital warts and laryngeal papillomas. High Risk Types can cause low-grade cervical cell abnormalities, high grade cervical cell abnormalities or anogenital cancers less common than cervical cancer, such as cancer of the vulva, vagina, penis and anus. The purpose of this paper is to explore and discuss differences in the vaginal microbiome and metabolome of women who have been classified as HPV positive vs women who have been classified as HPV negative. These differences are based upon a preliminary analysis which showed pathway enrichment of lipids, sphingolipids and estrogen when comparing women that were HPV positive with women that were HPV negative. This paper is exploratory in nature; as these topics hold great value for the rest of my dissertation, I briefly explored the following topics of interest in order to gain further insight: HPV, the vaginal microbiome, the life-cycle of HPV, HPV

Among the many arguments for mandatory HPV vaccination, the foremost is that it is an important medical achievement and a major public health milestone. This vaccine has proven to be one-hundred percent effective in preventing the 4 HPV strains that are responsible for seventy percent of cervical cancers and ninety percent of genital warts. In addition, no serious side effects have been identified. Because this vaccine is a preventive measure, administration before onset of sexual activity is ideal; however, even females who have been sexually active can still benefit from this vaccination (Perkins et al., 2010). Nationally and internationally, the HPV vaccine will significantly reduce disease burden by reducing monetary and psychological costs of invasive procedures that remove precancerous and cancerous lesions. By combining vaccination with routine Pap smear screening, these public health efforts have the remarkable opportunity to eradicate cervical cancer (Ramet et al., 2011).

Human papillomavirus, otherwise known as HPV, is the most prevalent sexually transmitted infection in North America (Dell et al. 2000; Gross 2014). Awareness of human papillomavirus is rather low and is often overshadowed by infections with much more noticeable symptoms such as gonorrhea and syphilis. The disease is usually associated with women due to its association with cervical cancer (Dell et al. 2000), and men are often overlooked. However, males are at risk just as much as females. There is plenty of evidence showing that human papillomavirus has detrimental effects to male health, yet females are usually the ones tested for the disease and are vaccinated. With today’s advancements in medicine, vaccinations should be administered to everyone to vastly reduce the prevalence of human papillomavirus, yet it is the most common STI. If males were vaccinated as much as females, highly preventable effects of human papillomavirus would diminish amongst the world population. Worldwide governments and public health agencies should fund HPV vaccination for males as well as females.

A sexually transmitted agent, human papillomavirus (HPV) is the causative agent for genital warts and most invasive forms of cervical cancer and other cancers of the anogenital tract (Trottier & Franco, 2006). In the United States (US), about 80 million people are infected with at least one strain of HPV, resulting to a prevalence rate of 50-80% among sexually active adolescents. This ranks HPV infections among the most commonly diagnosed sexually transmitted diseases (STDs) in the US (Faridi, Zahra, Khan, & Idrees, 2011; Gerend & Shepherd, 2012). According to (Gerend & Shepherd, 2012)), an estimated 12,000 cases of invasive cervical cancer, and 4,000 resulting deaths occur in the US annually due to low HPV vaccine uptake, thus predisposing sexually active adolescents to HPV infection (Baseman & Koutsky, 2005; Trottier & Franco, 2006). HPV vaccines have been shown to be safe and effective in preventing genital warts, and cancers of the anogenital tract, yet parental consent to vaccinate is still very low. The low vaccination rate can be attributed to vaccine safety concerns, “license” for adolescents to engage in sexual intercourse, lack of knowledge among the US population about HPV as a cause of genital warts and cancer, its mode of transmission, cost, and missed opportunities by HCPs to either recommend or administer the vaccine to adolescents (Dempsey & Zimet, 2008; Faridi et al., 2011). A child’s HCP is consistently cited as the determining factor in parental vaccine

The first reason for the implementation of HPV vaccination is to reduce the high mortality rate of cervical cancer. According to WHO (2017) cervical cancer is the fourth most common cancer among women and in 2012 more than 270,000 women died from the cancer, in particular 85 percent of the death occurred in less developed regions. That explains the cervical cancer is a serious threat to women’s health all round the world, especially in low and